Siglec15/TGF-β bispecific antibody mediates synergistic anti-tumor response against 4T1 triple negative breast cancer in mice.
Saved in:
| Title: | Siglec15/TGF-β bispecific antibody mediates synergistic anti-tumor response against 4T1 triple negative breast cancer in mice. |
|---|---|
| Authors: | Shen L; Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy, University of North Carolina Chapel Hill North Carolina USA., Schaefer AM; Department of Biomedical Engineering University of North Carolina Chapel Hill North Carolina USA., Tiruthani K; Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy, University of North Carolina Chapel Hill North Carolina USA., Wolf W; Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy, University of North Carolina Chapel Hill North Carolina USA., Lai SK; Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy, University of North Carolina Chapel Hill North Carolina USA.; Department of Biomedical Engineering University of North Carolina Chapel Hill North Carolina USA.; Department of Immunology and Microbiology University of North Carolina Chapel Hill North Carolina USA. |
| Source: | Bioengineering & translational medicine [Bioeng Transl Med] 2024 Mar 11; Vol. 9 (5), pp. e10651. Date of Electronic Publication: 2024 Mar 11 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: John Wiley & Sons Inc Country of Publication: United States NLM ID: 101689146 Publication Model: eCollection Cited Medium: Print ISSN: 2380-6761 (Print) Linking ISSN: 23806761 NLM ISO Abbreviation: Bioeng Transl Med Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
